We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00590096
First Posted: January 10, 2008
Last Update Posted: August 25, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Cincinnati
Information provided by:
Children's Hospital Medical Center, Cincinnati
  Purpose
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Condition
Neuroblastoma Pheochromocytoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Resource links provided by NLM:


Further study details as provided by Children's Hospital Medical Center, Cincinnati:

Enrollment: 1380
Study Start Date: January 1991
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma
Criteria

Inclusion Criteria:

  • Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00590096


Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
University of Cincinnati
Investigators
Principal Investigator: Michael J Gelfand, M.D. Children's Hospital Medical Center, Cincinnati
  More Information

Publications:
Responsible Party: Michael J. Gelfand M.D., Cincinnati Children's Hospital
ClinicalTrials.gov Identifier: NCT00590096     History of Changes
Other Study ID Numbers: CCHMC# 88-12-2
First Submitted: December 27, 2007
First Posted: January 10, 2008
Last Update Posted: August 25, 2009
Last Verified: January 2007

Keywords provided by Children's Hospital Medical Center, Cincinnati:
Neuroblastoma
Pheochromocytoma
MIBG

Additional relevant MeSH terms:
Neuroblastoma
Pheochromocytoma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Paraganglioma
Neuroendocrine Tumors